Li Auto Guides for Stronger Sales After Quarterly Profit Halves
By Jiahui Huang
Chinese electric-vehicle maker Li Auto guided for higher deliveries in the third quarter after a challenging quarter marked by a profit slump, slower sales growth and narrower margins.
The hybrid-vehicle specialist said Wednesday that its second-quarter net profit halved to 1.10 billion yuan, equivalent to $154.4 million. That topped the 854.5 million yuan consensus estimate of analysts in a FactSet poll.
Its revenue rose 11% to 31.68 billion yuan, beating analysts' estimate of 30.27 billion yuan. The automaker delivered 108,581 units during the period, up 25% from a year earlier. That slowed from the 53% vehicle sales growth in the first quarter.
For the third quarter, the company said it expects to deliver between 145,000 and 155,000 vehicles and post revenue of 39.4 billion yuan to 42.2 billion yuan.
Gross margin fell to 19.5% from 21.8% a year ago and 20.6% in the first quarter, the company said, citing a different product mix and pricing-strategy changes.
Write to Jiahui Huang at jiahui.huang@wsj.com
(END) Dow Jones Newswires
August 28, 2024 05:06 ET (09:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks